Glax­o­SmithK­line, Ox­ford un­veil new part­ner­ship pit­ting buzzy R&D ad­vances against neu­ro­log­i­cal dis­ease

When Glax­o­SmithK­line trum­pet­ed its re­turn to neu­ro­science with a $700 mil­lion up­front deal with Alec­tor this sum­mer, it tout­ed its ear­ly in­vest­ments in func­tion­al ge­nomics …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER